Literature DB >> 15640760

Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism.

Kazuhide Hayakawa1, Kenichi Mishima, Kohji Abe, Nobuyoshi Hasebe, Fumie Takamatsu, Hiromi Yasuda, Tomoaki Ikeda, Keiichiro Inui, Nobuaki Egashira, Katsunori Iwasaki, Michihiro Fujiwara.   

Abstract

Cannabidiol, a non-psychoactive constituent of cannabis, has been reported as a neuroprotectant. Cannabidiol and Delta(9)-tetrahydrocannabinol, the primary psychoactive constituent of cannabis, significantly decreased the infarct volume at 4 h in the mouse middle cerebral artery occlusion model. The neuroprotective effects of Delta(9)-tetrahydrocannabinol but not cannabidiol were inhibited by SR141716, a cannabinoid CB1 receptor antagonist, and were abolished by warming of the animals to the levels observed in the controls. Delta(9)-Tetrahydrocannabinol significantly decreased the rectal temperature, and the hypothermic effect was inhibited by SR141716. These results surely show that the neuroprotective effect of Delta(9)-tetrahydrocannabinol are via a CB1 receptor and temperature-dependent mechanisms whereas the neuroprotective effects of cannabidiol are independent of CB1 blockade and of hypothermia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15640760     DOI: 10.1097/00001756-200410250-00016

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  26 in total

1.  Cannabinoid disposition in oral fluid after controlled smoked cannabis.

Authors:  Dayong Lee; David M Schwope; Garry Milman; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-01-24       Impact factor: 8.327

Review 2.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 3.  Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.

Authors:  Janos Paloczi; Zoltan V Varga; George Hasko; Pal Pacher
Journal:  Antioxid Redox Signal       Date:  2017-07-18       Impact factor: 8.401

4.  Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model.

Authors:  Ming Zhang; Billy R Martin; Martin W Adler; Raj K Razdan; Jack I Jallo; Ronald F Tuma
Journal:  J Cereb Blood Flow Metab       Date:  2007-01-24       Impact factor: 6.200

5.  Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.

Authors:  E M Rock; D Bolognini; C L Limebeer; M G Cascio; S Anavi-Goffer; P J Fletcher; R Mechoulam; R G Pertwee; L A Parker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

7.  Unique effects of compounds active at both cannabinoid and serotonin receptors during stroke.

Authors:  Ming Zhang; Anu Mahadevan; Mukkanti Amere; Hongbo Li; Doina Ganea; Ronald F Tuma
Journal:  Transl Stroke Res       Date:  2012-07-26       Impact factor: 6.829

8.  Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death.

Authors:  Hao Pan; Partha Mukhopadhyay; Mohanraj Rajesh; Vivek Patel; Bani Mukhopadhyay; Bin Gao; György Haskó; Pál Pacher
Journal:  J Pharmacol Exp Ther       Date:  2008-12-12       Impact factor: 4.030

Review 9.  Cannabinoids in experimental stroke: a systematic review and meta-analysis.

Authors:  Timothy J England; William H Hind; Nadiah A Rasid; Saoirse E O'Sullivan
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

Review 10.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.